

1 **SARS-CoV-2 Omicron variant, lineage BA.1, is associated with lower viral load in**
2 **nasopharyngeal samples compared to Delta variant.**

3 Célia Sentis^{1,2}, Geneviève Billaud¹, Antonin Bal^{1,2,3}, Emilie Frobert^{1,2}, Maude Bouscambert¹,
4 Gregory Destras^{1,2,3}, Laurence Josset^{1,2,3}, Bruno Lina^{1,2}, Florence Morfin^{1,2}, Alexandre
5 Gaymard^{1,2}, and the COVID-Diagnosis HCL Study Group

6
7 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
8 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon,
9 France.

10 ² CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon,
11 Inserm,
12 U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon,
13 France.

14 ³ GenEPII platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon France

15
16 **Corresponding author:**

17 Alexandre Gaymard, Pharm.D, Ph.D
18 Praticien hospitalo-universitaire (PHU)
19 Laboratoire de Virologie (Pr B. Lina)
20 Institut des Agents Infectieux
21 Hospices Civils de Lyon
22 Phone: +33 (0)4 72 07 10 53
23 Email: alexandre.gaymard@chu-lyon.fr

24
25 **Abstract (74/75)**

26 High viral load in upper respiratory tract specimens observed for Delta cases may contributed
27 to its increased infectivity compared to the Alpha variant. Herein, we showed that the RT-
28 PCR Ct values in Health Care Workers sampled within five days after symptom onset were
29 significantly higher for Omicron cases than Delta cases (+2.84 Ct, p=0.008). This result
30 comfort the studies showing that the increased transmissibility of Omicron is related to other
31 mechanisms than higher virus excretion.

32 **Keywords:**

33 SARS-CoV-2; COVID-19, viral load; variants

34

35 **Conflic of interest**

36 None

37

38 **Funding statement:**

39 No specific funding was obtain for this study.

40

41 At the end of 2020, the first SARS-CoV-2 variants of concern (VOC), named Alpha, was
42 detected and became the main variant just a few months after (1,2). Then, Delta variant firstly
43 detected in March 2021 rapidly spread worldwide and became the major variant during the
44 second part of 2021. These VOCs demonstrated increased infectivity that was related to better
45 affinity for ACE2 cellular receptor and higher viral load in respiratory tract samples (3–7).

46 During the last trimester of 2021, a new variant named Omicron, emerged and was
47 immediately classified as a VOC due to the large number of mutations found in the spike
48 protein, including several mutations known to be associated with higher transmissibility
49 and/or immune escape (8,9). The Omicron variant is the most contagious form of SARS-CoV-
50 2 known so far and became dominant worldwide in a few weeks (10). However, it is not yet
51 documented if its enhanced infectivity is also related to a higher viral load as reported for
52 other variants(5,6).

53 **Sample collection and virological testing**

54 To determine if the Omicron variant's spread is related to higher viral loads compared to
55 Delta variant, we collected nasopharyngeal swabs from screening center dedicated to health
56 care workers and family at the University Hospital of Lyon, France. Data from samples taken
57 between 12/1/2021 and 12/31/2021 were collected, a period with circulation of Delta variant
58 and emergence of Omicron variants in Lyon, France (Figure 1A). The French national
59 strategy includes screening test specific for SARS-CoV-2, positive samples are then tested by
60 RT-PCR targeting some mutations (E484K, L452R and K417N) and by whole genome
61 sequencing. SARS-CoV-2 detection was performed using the cobas® 6800 SARS-CoV-2
62 assay (Roche, Switzerland). Cycle threshold (Ct) for the RdRp target was used as a proxy to
63 evaluate SARS-CoV-2 viral load. Mutations screening were performed using TaqMan SARS-
64 CoV-2 Mutation Panel (Thermofisher, USA) and whole genome sequencing with COVIDSeq
65 assay (Illumina, USA). All statistical analyses were conducted using GraphPad Prism®
66 (version 8.0.2). Mean Ct difference between groups was assessed using the Student's T test or
67 Mann-Whitney test, as appropriate. Categorical variables were compared using the Chi-square
68 test or Fisher's exact test.

69 **Ct-values according to day post-symptom onset and age**

70 Patients infected with Omicron variant had a lower viral load (higher Ct value) compared to
71 patients infected with Delta variant (22.7 for Delta vs 24.4 for Omicron, $p=0.006$) (Figure
72 2A). This observation was only confirmed for patients with symptoms appearing less than 5

73 days before sampling (21.7 for Delta vs 23.8 for Omicron, $p=0.008$). Moreover, the largest
74 difference was found in patients with symptom onset under 1 day, with viral load almost 1
75 \log_{10} lower with Omicron variant compared to Delta variant (21.3 for Delta vs 24.2 for
76 Omicron, $p = 0.035$) (Figure 2A and Supplementary 1). Significant viral load differences were
77 found only for patients over 40 years old (20.9 for Delta vs 23.6 for Omicron, $p=0.006$)
78 (Supplementary 1, Figure 2B) with higher viral load found in patients infected by Delta
79 variant.

80 **Ct-values according to vaccination status**

81 In order to limit misinterpretation related to the vaccination status, we classified patients into
82 five categories according to French vaccination strategy: not vaccinated, partially vaccinated
83 (1 dose or 1 infection), completely vaccinated (2 doses or 1 dose and 1 infection), boosted (3
84 doses or 2 doses and 1 infection) or unknown (data not available). Regarding patients
85 completely vaccinated, Omicron variant was characterized by a lower viral load compared to
86 patients infected by the Delta variant (21.7 for Delta vs 24.3 for Omicron, $p=0.01$). In boosted
87 patients the inverse trend was observed with a higher viral load during Omicron variant
88 infection (25.49 for Delta vs 23.69 for Omicron $p=0.09$) (Figure 2C). Of note, the proportion
89 of third dose (boosted) was higher at the end of December compared to the beginning of
90 December (26.3% week 48 vs 61.7% week 52, Figure 1B).

91 **Discussion**

92 For the previous Alpha and Delta VOCs higher transmission rates have been related to higher
93 viral loads (5–7). In contrast, our results showed a higher Ct value (+2.84), reflecting lower
94 viral load ($-0.85 \log_{10}$), for patients infected by Omicron, compared to patients infected by
95 Delta variant. This is in agreement with a recent study reporting patients follow-up after Delta
96 and Omicron infection showing a peak viral load at a Ct value of 23.3 for Omicron and 20.5
97 for Delta (11). In another study, Puhach *et al*, reported a low correlation between RNA
98 genome copies and infectious virus shedding evaluated by viral culture (12). Regarding
99 Omicron, they showed a trend to lower viral load compared to Delta (RNA genome copies
100 and infectious virus titers) that was not significant probably due to low patients number in the
101 Omicron group ($n=18$) (12). These data combined with ours could suggest that higher
102 infectiousness of Omicron may not be related to an increased viral load as reported for
103 previous variants. Complete mechanisms driving the higher transmissibility of Omicron
104 variant are still unknown. Infectiousness could be multifactorial and related to background

105 immunity, respiratory symptoms (cough, sneeze), duration of viral excretion, age and viral
106 parameters such as new viral entry mechanism (11,13,14).

107 The present study has several limitations as viral load was estimated by Ct without specific
108 quantification and normalization. Only BA.1 lineage were circulating in France during the
109 study period and results for other Omicron lineage such as BA.2 could differ. Our results were
110 also impacted by the vaccination strategy. Omicron viral load was lower for patients with
111 complete vaccination but the inverse trend was observed for boosted patients. This might be
112 related to a lower susceptibility to neutralizing antibodies for Omicron variant compared to
113 Delta variant. Boosted patients infected by Delta variant might be more protected than
114 patients infected by Omicron, which would explain the lower viral load in Delta group
115 (8,15,16). These results should be taken carefully as more patients with boosted vaccination
116 were observed in the Omicron infection group and counterwise more patients with complete
117 vaccination were observed in the Delta infection group (Table 1). This observation has to be
118 related to the National vaccination strategy, as French government announced a mandatory
119 third dose vaccination to health care workers during December. In addition, most of positive
120 samples for Delta variant were collected at the beginning of December. Omicron variant
121 began to be detected in France mid- December 2021 and overthrow Delta variant during the
122 last week of December (Figure 1A). A more in-depth study taking into account vaccination
123 status, time since the last injection and antibody levels will be necessary to better understand
124 the impact of the immune response on the infection by different SARS-CoV-2 variants.

125 Finally, lower viral load during Omicron infection might impact viral diagnosis. Even if rapid
126 antigenic testing are still able to detect Omicron, higher Ct values in Omicron cases may be
127 associated with an increased number of false negative results compared to Delta. This must
128 not preclude from using antigenic testing devices, but the interpretation may be cautious.
129 Moreover, patient monitoring using Ct values should be cautiously interpreted according to
130 each patient situation. Ct value could be a poor indicator of infectiousness, especially in
131 presence of neutralizing antibodies. In the context of a largely vaccinated population, new
132 criteria must be defined and new biomarkers have to be looked for.

133

134 **References**

- 135 1. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission
136 of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and
137 genetic data. *Infectious Diseases (except HIV/AIDS)*; 2021 janv [cité 22 févr 2021].
138 Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2020.12.30.20249034>
- 139 2. Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early
140 assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1
141 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. *Eurosurveillance* .
142 4 mars 2021 [cité 19 janv 2022];26(9). Disponible sur:
143 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.9.2100133>
- 144 3. Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular
145 dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the
146 combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces
147 conformational change greater than N501Y mutant alone, potentially resulting in an escape
148 mutant . *Biophysics*; 2021 janv [cité 7 févr 2021]. Disponible sur:
149 <http://biorxiv.org/lookup/doi/10.1101/2021.01.13.426558>
- 150 4. Laffeber C, de Koning K, Kanaar R, Lebbink JHG. Experimental Evidence for
151 Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants. *J Mol Biol*. juill
152 2021;433(15):167058.
- 153 5. Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, et al.
154 The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical
155 variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. *J Infect*. oct
156 2021;83(4):e1–3.
- 157 6. Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-Variant SARS-
158 CoV-2 Lineage B1.1.7 Is Associated With Significantly Higher Viral Load in Samples Tested
159 by TaqPath Polymerase Chain Reaction. *J Infect Dis*. 28 mai 2021;223(10):1666–70.
- 160 7. Blanquart F, Abad C, Ambroise J, Bernard M, Cosentino G, Giannoli J-M, et al.
161 Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha
162 variants and within-host viral load dynamics in the community, France, June to July 2021.
163 *Eurosurveillance* . 16 sept 2021 [cité 25 janv 2022];26(37). Disponible sur:
164 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.37.2100824>
- 165 8. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced
166 Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal
167 Antibodies . *Infectious Diseases (except HIV/AIDS)*; 2021 déc [cité 10 janv 2022].
168 Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2021.12.07.21267432>
- 169 9. Willett BJ, Grove J, MacLean OA, Wilkie C, Logan N, Lorenzo GD, et al. The hyper-
170 transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine
171 escape and a switch in cell entry mechanism . *Infectious Diseases (except HIV/AIDS)*; 2022
172 janv [cité 10 janv 2022]. Disponible sur:
173 <http://medrxiv.org/lookup/doi/10.1101/2022.01.03.21268111>
- 174 10. Ito K, Piantham C, Nishiura H. Relative Instantaneous Reproduction Number of

- 175 Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. *J Med Virol.*
176 30 déc 2021;jmv.27560.
- 177 11. Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. Viral dynamics
178 and duration of PCR positivity of the SARS-CoV-2 Omicron variant. *medRxiv.* 1 janv
179 2022;2022.01.13.22269257.
- 180 12. Puhach O, Adea K, Hulo N, Sattoune P, Genecand C, Iten A, et al. Infectious viral
181 load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and
182 Omicron . *Infectious Diseases (except HIV/AIDS);* 2022 janv [cité 14 janv 2022]. Disponible
183 sur: <http://medrxiv.org/lookup/doi/10.1101/2022.01.10.22269010>
- 184 13. Bekliz M, Adea K, Vetter P, Eberhardt CS, Hosszu-Fellous K, Vu D-L, et al.
185 Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and
186 Omicron by mRNA vaccination and infection-derived immunity through homologous and
187 heterologous variants . *Infectious Diseases (except HIV/AIDS);* 2021 déc [cité 14 janv 2022].
188 Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2021.12.28.21268491>
- 189 14. Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, et al. The
190 SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial
191 cultures and efficiently uses the endosomal route of entry . *Microbiology;* 2022 janv [cité 14
192 janv 2022]. Disponible sur: <http://biorxiv.org/lookup/doi/10.1101/2021.12.31.474653>
- 193 15. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
194 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature.* 12 août
195 2021;596(7871):276-80.
- 196 16. Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al. Neutralization of
197 SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. 2022;6.
- 198
- 199

200 **Data availability**

201 SARS-CoV-2 whole genomes sequenced in this study were deposited in the GISAID
202 database.

203 **Ethics statement**

204 Ethics committee of Hospices Civils de Lyon gave ethical approval for this work (approval
205 number 22_787). The investigations were carried out in accordance with the General Data
206 Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French
207 data protection law (Law 78–17 on 06/01/1978 and Décret 2019–536 on 29/05/2019).
208 Samples were collected for regular clinical management, with no additional samples for the
209 purpose of this study. Patients were informed and their non-objection approval was
210 confirmed.

211 **COVID-Diagnosis HCL Study Group**

212 Jean-Sébastien Casalegno, Vanessa Escuret, Vinca Icard, Marion Jeannoel, Marie-Paule
213 Milon, Yahia Mekki, Christophe Ramière, Caroline Scholtès, Bruno Simon, Jean-Claude
214 Tardy, Mary-Anne Trabaud, Isabelle Schuffenecker, Martine Valette.

215 All authors in the study group are affiliated to :

216 Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
217 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon,

218 **Authors' contributions:**

219 CS, FM, and AG designed the study. GB, EF, MB supervised the RT-PCR analysis. AB GD
220 LJ and AG supervised the variant identification. AG wrote the protocol of the study. CS, FM
221 and AG collected the data. CS, BL, FM and AG analysed the whole results. CS performed the
222 statistical analyses and provided the Figures and Tables. The members of the COVID-


223 Diagnosis HCL Study Group contributed to the laboratory analysis. CS, BL, FM and AG

224 wrote the manuscript. All the authors corrected and approved the final manuscript.

	Delta (n=86)	Omicron (n=129)	P-value
Sex			
Women	65.1 % (56)	62.8% (81)	0.77
Men	34.9% (30)	37.2% (48)	
Index ratio	1.86	1.68	
Age			
20-30	38.4% (33)	45.8% (59)	0.32
31-40	33.7% (29)	24.0% (31)	0.12
41-50	16.3% (14)	18.6% (24)	0.71
> 51 years old	11.6% (10)	11.6% (15)	> 0.99
Symptoms			
Asymptomatic	33.7% (29)	26.3% (34)	0.28
Day before or day of sampling	24.4% (21)	28.7% (37)	0.53
2 to 4 days before sampling	34.9% (30)	28.7% (37)	0.37
5 to 7 days before sampling	5.8% (5)	12.4% (16)	0.16
8 to 14 days before sampling	1.2% (1)	3.9% (5)	0.4
Vaccination status			
Not vaccinated	2.3% (2)	5.4% (7)	0.32
Partial : 1 dose or 1 infection	8.1% (7)	6.9% (9)	0.79
Complete : 2 doses or 1 dose + 1 infection	43% (37)	24.0% (31)	0.004
Boosted : 3 doses or 2 doses + 1 infection	25.6% (22)	41.9% (54)	0.02
Unknown	20.9% (18)	21.7% (28)	> 0.99


225 *Table 1: Demographic data. P-value was calculated with Fischer test.*

227 A/



228

229 B/



230


231 *Figure 1Aa: Proportion of samples positive for the Delta or Omicron variant on a weekly basis. Week 48 (Delta, n=31),*
232 *week 49 (Delta, n=16), week 50 (Delta, n=16); week 51 (Delta, n=18 ; Omicron, n=30), week 52 (Delta, n= 8 ; Omicron,*
233 *n=99).*

234 *Figure 1B: Vaccination status of patients on a weekly basis. Patients not vaccinated, partially vaccinated, or with unknown*
235 *status were removed from this graph. Week 48 (complete, n= 14; boosted, n = 5), week 49 (complete, n =9 ; boosted, n =4),*
236 *week 50 (complete, n= 9 ; boosted, n =5), week 51 (complete, n = 8 ; boosted, n = 17), week 52 (complete, n = 31 ; boosted,*
237 *n= 50).*

238


239

240 A/




241

242 B/



243

244 C/



245

246 *Figure 2: RT-PCR Cycle threshold values for Delta or Omicron*
 247 *2A: Cycle threshold of Delta or Omicron variant according*
 248 *to symptoms. Global analysis included all samples (Delta, n=86, Omicron, n=129). Asymptomatic patients (Delta, n=29 and*
 249 *Omicron, n=34), symptoms appearing less than 5 days prior sampling (Delta, n=51 and Omicron, n=74) and symptoms*
 250 *appearing more than 5 days prior sampling (Delta, n=6 and Omicron, n=21). 2B: Cycle threshold of Omicron or Delta*
 251 *variant by age. Ct was analysed for patients under 40 years old (Delta, n= 62 and Omicron, n=90) and patients over 40*
 252 *years old (Delta, n=24 and Omicron, n=39). 2C: Cycle threshold of Delta or Omicron variant according to vaccination*
 253 *status. Vaccination was considered complete when patient received 2 doses or 1 dose and 1 infection (Delta, n= 37 and*
 254 *Omicron, n=31) and boosted when patients received 3 doses or 2 doses and 1 infection (Delta, n=22 and Omicron, n=54).*
*P-value was calculated with Student test. ns = not significant, * = <0.05, ** = <0.01.*